Pfizer’s mRNA flu vaccine outperformed the standard flu shot in a Phase 3 clinical trial, according to results published ...

Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...

LOS ANGELES -- The COVID-19 vaccines made by Pfizer and Moderna both require two doses to be administered, several weeks apart, for them to be fully effective. But there has been some scientific ...

A new mRNA-based flu vaccine from Pfizer has shown greater effectiveness than the standard flu shot in a large Phase 3 trial, according to results published in the New England Journal of Medicine. The ...

SAN FRANCISCO -- As more people are eligible to get vaccinated, reports of side effects after the second Pfizer and Moderna shots are surfacing. Dr. Robert Wachter, chief of medicine at UCSF says many ...

SAN FRANCISCO -- Another COVID-19 vaccine -- AstraZeneca -- is poised to arrive in the U.S., bringing a fourth option for Americans. Each vaccine is administered slightly differently, some can result ...

The excitement of two COVID-19 vaccines with more than 90 percent efficacy is undeniable. In November, both Pfizer and Moderna announced its scientists had developed vaccines with efficacy at or near ...

CHICAGO (WLS) -- The Johnson & Johnson vaccine continues to be put on hold after a CDC panel said it needs more time to look into claims of dangerous blood clots. The United Center mass vaccination ...

The Food and Drug Administration today authorized both Pfizer and Moderna to give a second booster dose of their COVID-19 vaccines to individuals aged 50 and older and to those who are ...

The U.S. Food and Drug Administration has authorized booster shots of the Moderna and Pfizer COVID-19 vaccines for all adults ages 18 and older. On Friday, the FDA announced it had amended the ...

Shares of COVID-19 vaccine makers Pfizer Inc (NYSE:PFE), BioNTech SE ADR (NASDAQ:BNTX) and Moderna Inc (NASDAQ:MRNA) are trading lower Friday following a Washington Post report that Trump ...